FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313222418> ?p ?o ?g. }

• W4313222418 endingPage "234" @default.
• W4313222418 startingPage "234" @default.
• W4313222418 abstract "Introduction: Glyburide is a medication that has been theorized to prevent cerebral edema formation in acute ischemic stroke (AIS). The purpose of this study was to describe the impact of oral glyburide on cerebral edema formation when used in patients who had a diagnosis of AIS. Methods: This study was a single-center, retrospective chart review that included all patients at least 18 years of age with a confirmed diagnosis of AIS who had received at least one dose of oral glyburide for the prevention of cerebral edema from January 1st, 2018 to March 31st, 2022. The primary outcome was to describe the percentage of patients requiring treatment or intervention for cerebral edema management following glyburide initiation. Results: A total of 44 patients were included in the primary outcome, with 6 (14%) patients requiring intervention for cerebral edema after glyburide initiation. When patients were evaluated by the number of doses received, 20 (45%) patients were in the partial duration group (defined as receipt of 1-4 doses of oral glyburide) and 24 (55%) patients were in the full duration group (defined as receipt of 5-7 doses of oral glyburide). There was a numerically lower rate of intervention for cerebral edema in the partial duration group as compared with the full duration group (10% vs 17%). Additionally, a full duration of glyburide therapy was associated with a numerically higher rate of hypoglycemia (23%) compared to a partial duration of therapy (5%). Lastly, there was a numerically higher rate of mortality in the partial duration group as compared to the full duration group (43% vs 31%). Conclusions: This exploratory study found that patients receiving a longer duration of treatment with oral glyburide required higher or similar rates of intervention for cerebral edema as compared to a shorter duration of therapy. Further, a longer duration of therapy was associated with a numerically higher rate of hypoglycemia. These results suggest that the benefits of glyburide may be outweighed by the risk of hypoglycemia for patients receiving 5-7 doses of oral glyburide. The risk and benefits of oral glyburide should be carefully evaluated when starting a patient on this medication for the prevention of cerebral edema following AIS." @default.
• W4313222418 created "2023-01-06" @default.
• W4313222418 creator A5001221492 @default.
• W4313222418 creator A5019241609 @default.
• W4313222418 creator A5043451552 @default.
• W4313222418 creator A5089039408 @default.
• W4313222418 date "2022-12-15" @default.
• W4313222418 modified "2023-10-18" @default.
• W4313222418 title "494: ORAL GLYBURIDE FOR THE PREVENTION OF CEREBRAL EDEMA IN ACUTE ISCHEMIC STROKE" @default.
• W4313222418 doi "https://doi.org/10.1097/01.ccm.0000907704.57411.81" @default.
• W4313222418 hasPublicationYear "2022" @default.
• W4313222418 type Work @default.
• W4313222418 citedByCount "0" @default.
• W4313222418 crossrefType "journal-article" @default.
• W4313222418 hasAuthorship W4313222418A5001221492 @default.
• W4313222418 hasAuthorship W4313222418A5019241609 @default.
• W4313222418 hasAuthorship W4313222418A5043451552 @default.
• W4313222418 hasAuthorship W4313222418A5089039408 @default.
• W4313222418 hasBestOaLocation W43132224181 @default.
• W4313222418 hasConcept C127413603 @default.
• W4313222418 hasConcept C141071460 @default.
• W4313222418 hasConcept C2777318445 @default.
• W4313222418 hasConcept C2779493303 @default.
• W4313222418 hasConcept C2780645631 @default.
• W4313222418 hasConcept C2780886150 @default.
• W4313222418 hasConcept C42219234 @default.
• W4313222418 hasConcept C544519230 @default.
• W4313222418 hasConcept C71924100 @default.
• W4313222418 hasConcept C78519656 @default.
• W4313222418 hasConceptScore W4313222418C127413603 @default.
• W4313222418 hasConceptScore W4313222418C141071460 @default.
• W4313222418 hasConceptScore W4313222418C2777318445 @default.
• W4313222418 hasConceptScore W4313222418C2779493303 @default.
• W4313222418 hasConceptScore W4313222418C2780645631 @default.
• W4313222418 hasConceptScore W4313222418C2780886150 @default.
• W4313222418 hasConceptScore W4313222418C42219234 @default.
• W4313222418 hasConceptScore W4313222418C544519230 @default.
• W4313222418 hasConceptScore W4313222418C71924100 @default.
• W4313222418 hasConceptScore W4313222418C78519656 @default.
• W4313222418 hasIssue "1" @default.
• W4313222418 hasLocation W43132224181 @default.
• W4313222418 hasLocation W43132224182 @default.
• W4313222418 hasOpenAccess W4313222418 @default.
• W4313222418 hasPrimaryLocation W43132224181 @default.
• W4313222418 hasRelatedWork W1927888013 @default.
• W4313222418 hasRelatedWork W1967290285 @default.
• W4313222418 hasRelatedWork W2042325978 @default.
• W4313222418 hasRelatedWork W2144995224 @default.
• W4313222418 hasRelatedWork W2348158266 @default.
• W4313222418 hasRelatedWork W2351127419 @default.
• W4313222418 hasRelatedWork W2412194159 @default.
• W4313222418 hasRelatedWork W2422704660 @default.
• W4313222418 hasRelatedWork W2555536348 @default.
• W4313222418 hasRelatedWork W68621166 @default.
• W4313222418 hasVolume "51" @default.
• W4313222418 isParatext "false" @default.
• W4313222418 isRetracted "false" @default.
• W4313222418 workType "article" @default.